Abstract
Objective
To investigate the association between new or enlarging T2-weighted (w) white matter (WM) lesions adjacent to the ventricle wall, deep grey matter (DGM) atrophy and lateral ventricular enlargement in multiple sclerosis (MS).
Methods
Patients derived from the Genetic Multiple Sclerosis Associations study. Lateral ventricles and DGM were segmented fully automated at baseline and 5 years follow-up using Automatic Lateral Ventricle delineation (ALVIN) and Multiple Automatically Generated Templates brain segmentation algorithm (MAgeT), respectively. T2w and T1w lesions were manually segmented. To investigate the association between lesion distance to the ventricle wall and the lateral ventricle volume, we parcellated the WM into concentric periventricular bands using FMRIB Software Library. Associations between clinical and MRI parameters were assessed in generalized linear models using generalized estimating equations for repeated measures.
Results
We studied 127 MS patients. Lateral ventricles enlarged on average by 2.4%/year. Patients with new/enlarging T2w WM lesions between baseline and follow-up at 5 years had accelerated lateral ventricular enlargement compared with patients without (p = 0.004). This was true in a multivariable analysis adjusted for age, gender, and whole brain atrophy. When looking at the T2w lesions in different periventricular bands, we found the strongest association between new/enlarging T2w lesions and lateral ventricle enlargement for WM lesions adjacent to the ventricle system (p < 0.001). Moreover, and indepedent of new/enlarging WM lesions, DGM atrophy was associated with ventricular enlargement. In a multivariable analysis, this was driven by thalamic atrophy (p < 0.001).
Conclusion
New/enlarging T2w lesions adjacent to the ventricle system and thalamic atrophy are independently associated with lateral ventricular enlargement in MS.
Similar content being viewed by others
References
Miller DH, Barkhof F, Frank JA et al (2002) Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain J Neurol 125:1676–1695
Uher T, Horakova D, Kalincik T et al (2015) Early magnetic resonance imaging predictors of clinical progression after 48 months in clinically isolated syndrome patients treated with intramuscular interferon β-1a. Eur J Neurol 22:1113–1123. https://doi.org/10.1111/ene.12716
Zivadinov R, Uher T, Hagemeier J et al (2016) A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients. Mult Scler 22:1709–1718. https://doi.org/10.1177/1352458516629769
Eshaghi A, Prados F, Brownlee WJ et al (2018) Deep gray matter volume loss drives disability worsening in multiple sclerosis. Ann Neurol 83:210–222. https://doi.org/10.1002/ana.25145
Dalton CM, Brex PA, Jenkins R et al (2002) Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis. J Neurol Neurosurg Psychiatry 73:141–147. https://doi.org/10.1136/jnnp.73.2.141
Zivadinov R, Horakova D, Bergsland N et al (2019) A serial 10-year follow-up study of atrophied brain lesion volume and disability progression in patients with relapsing–remitting MS. Am J Neuroradiol 40:446–452. https://doi.org/10.3174/ajnr.A5987
Baranzini SE, Galwey NW, Wang J et al (2009) Pathway and network-based analysis of genome-wide association studies in multiple sclerosis. Hum Mol Genet 18:2078–2090. https://doi.org/10.1093/hmg/ddp120
Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452
Fischer JS, Rudick RA, Cutter GR, Reingold SC (1999) The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler 5:244–250. https://doi.org/10.1177/135245859900500409
Smith A (1989) Symbol digit modalities test
Schwid S, Goodman A, McDermott M et al (2019) Quantitative functional measures in MS: what is a reliable change? Neurology 23:1294–1296
Hauser SL, Bar-Or A, Comi G et al (2017) Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med 376:221–234. https://doi.org/10.1056/NEJMoa1601277
Smith SM, Jenkinson M, Woolrich MW et al (2004) Advances in functional and structural MR image analysis and implementation as FSL. NeuroImage 23(Suppl 1):S208–S219. https://doi.org/10.1016/j.neuroimage.2004.07.051
Rudick RA, Fisher E, Lee JC et al (1999) Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 53:1698–1704
Smith SM, Zhang Y, Jenkinson M et al (2002) Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. NeuroImage 17:479–489
Battaglini M, Jenkinson M, Stefano ND (2012) Evaluating and reducing the impact of white matter lesions on brain volume measurements. Hum Brain Mapp 33:2062–2071. https://doi.org/10.1002/hbm.21344
Magon S, Chakravarty MM, Amann M et al (2014) Label-fusion-segmentation and deformation-based shape analysis of deep gray matter in multiple sclerosis: the impact of thalamic subnuclei on disability. Hum Brain Mapp 35:4193–4203. https://doi.org/10.1002/hbm.22470
Kempton MJ, Underwood TSA, Brunton S et al (2011) A comprehensive testing protocol for MRI neuroanatomical segmentation techniques: evaluation of a novel lateral ventricle segmentation method. NeuroImage 58:1051–1059. https://doi.org/10.1016/j.neuroimage.2011.06.080
Battaglini M, Jenkinson M, De Stefano N (2012) Evaluating and reducing the impact of white matter lesions on brain volume measurements. Hum Brain Mapp 33:2062–2071. https://doi.org/10.1002/hbm.21344
R Development Core Team (2008) R: A language and environment for statistical computing. Vienna
Kalkers NF, Ameziane N, Bot JCJ et al (2002) Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype. Arch Neurol 59:1572–1576
Simon JH, Jacobs LD, Campion MK et al (1999) A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 53:139–148
Varosanec M, Uher T, Horakova D et al (2015) Longitudinal Mixed-Effect Model Analysis of the Association between Global and Tissue-Specific Brain Atrophy and Lesion Accumulation in Patients with Clinically Isolated Syndrome. AJNR Am J Neuroradiol 36:1457–1464. https://doi.org/10.3174/ajnr.A4330
Fox J, Kraemer M, Schormann T et al (2016) Individual Assessment of Brain Tissue Changes in MS and the Effect of Focal Lesions on Short-Term Focal Atrophy Development in MS: a Voxel-Guided Morphometry Study. Int J Mol Sci. https://doi.org/10.3390/ijms17040489
Wolinsky JS (2016) Confavreux lecture: where do we go from here with imaging in clinical trials for MS? ECTRIMS 147083:256
Henry RG, Shieh M, Amirbekian B et al (2009) Connecting white matter injury and thalamic atrophy in clinically isolated syndromes. J Neurol Sci 282:61–66. https://doi.org/10.1016/j.jns.2009.02.379
Vercellino M, Masera S, Lorenzatti M et al (2009) Demyelination, inflammation, and neurodegeneration in multiple sclerosis deep gray matter. J Neuropathol Exp Neurol 68:489–502. https://doi.org/10.1097/NEN.0b013e3181a19a5a
Cifelli A, Arridge M, Jezzard P et al (2002) Thalamic neurodegeneration in multiple sclerosis. Ann Neurol 52:650–653. https://doi.org/10.1002/ana.10326
Turner B, Ramli N, Blumhardt LD, Jaspan T (2001) Ventricular enlargement in multiple sclerosis: a comparison of three-dimensional and linear MRI estimates. Neuroradiology 43:608–614
Miller DH, Barkhof F, Frank JA et al (2002) Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain J Neurol 125:1676–1695
Zivadinov R, Medin J, Khan N et al (2018) Fingolimod’s Impact on MRI Brain Volume Measures in Multiple Sclerosis: results from MS-MRIUS. J Neuroimaging Off J Am Soc Neuroimaging. https://doi.org/10.1111/jon.12518
Turner B, Lin X, Calmon G et al (2003) Cerebral atrophy and disability in relapsing-remitting and secondary progressive multiple sclerosis over four years. Mult Scler 9:21–27. https://doi.org/10.1191/1352458503ms868oa
Zivadinov R, Havrdová E, Bergsland N et al (2013) Thalamic atrophy is associated with development of clinically definite multiple sclerosis. Radiology 268:831–841. https://doi.org/10.1148/radiol.13122424
Uher T, Horakova D, Bergsland N et al (2014) MRI correlates of disability progression in patients with CIS over 48 months. NeuroImage Clin 6:312–319. https://doi.org/10.1016/j.nicl.2014.09.015
Acknowledgements
We thank all patients participated in the Genetic Multiple Sclerosis Associations study.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
Tim Sinnecker is part-time employee of the Medical Image Analysis Center Basel. Esther Ruberte has nothing to disclose. Sabine Schädelin has nothing to disclose. Vera Canova has nothing to disclose. Michael Amann has nothing to disclose. Yvonne Naegelin has nothing to dislose. Iris-Katharina Penner has nothing to disclose. Jannis Müller has nothing to disclose. Jens Kuhle received speaker fees, research support, travel support, and/or served on advisory boards by ECTRIMS, Swiss MS Society, Swiss National Research Foundation [320030_160221], University of Basel, Bayer, Biogen, Genzyme, Merck, Novartis, Protagen AG, Roche, Teva. Bernhard Décard received travel support and/or fees for the institution [University Hospital Basel] from advisory boards or speaker fees from Allmirall, Biogen, Genzyme, Roche, Teva and Novartis, that were used exclusively for research support. Tobias Derfuss received speaker fees, research support, travel support, and/or served on Advisory Boards or Steering Committees of Novartis Pharma, Merck, Biogen, Teva, Bayer-Schering, GeNeuro, Mitsubishi Pharma, MedDay, Roche, and Genzyme; he received research support from Biogen, Novartis, Swiss National Research Foundation, University of Basel, and Swiss MS Society. Ludwig Kappos´s institution [University Hospital Basel] received and used exclusively for research support: steering committee, advisory board, and consultancy fees from Actelion, Addex, Bayer HealthCare, Biogen, Biotica, Celgene/Receptos, Genzyme, Lilly, Merck, Mitsubishi, Novartis, Ono Pharma, Pfizer, Sanofi, Santhera, Siemens, Teva, UCB, Xenoport; speaker fees from Bayer HealthCare, Biogen, Merck, Novartis, Sanofi, Teva; support of educational activities from Bayer HealthCare, Biogen, CSL Behring, Genzyme, Merck, Novartis, Sanofi, Teva; grants from Bayer HealthCare, Biogen, F. Hoffmann-La Roche Ltd, Merck, Novartis, the European Union, the Roche Research Foundations, the Swiss Multiple Sclerosis Society, the Swiss National Research Foundation. Cristina Granziera has nothing to disclose. Jens Wuerfel is CEO of the Medical Image Analysis Center Basel. Stefano Magon is employee from F. Hoffmann-La Roche AG. Özgür Yaldizli´s institution University Hospital Basel received grants from ECTRIMS/MAGNIMS, University of Basel, Pro Patient Stiftung University Hospital Basel, Free Academy Basel, Swiss Multiple Sclerosis Society and advisory board fees from Sanofi Genzyme, Biogen and Novartis Poland exclusively used for support of research and educational activities.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Sinnecker, T., Ruberte, E., Schädelin, S. et al. New and enlarging white matter lesions adjacent to the ventricle system and thalamic atrophy are independently associated with lateral ventricular enlargement in multiple sclerosis. J Neurol 267, 192–202 (2020). https://doi.org/10.1007/s00415-019-09565-w
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-019-09565-w